Species specificity of an adrenal androgen-mediated kill-switch triggered by p53 inactivation release_bquspnhusnel7av63lagiarboy

by Jonathan Nyce

Published in Translational Medicine Reports by PAGEPress Publications.

2017  

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is an oncoprotein that is regulated by the p53 tumor suppressor. Mutant p53 loses the ability to inhibit G6PD, and loss of G6PD control clearly plays a role in oncogenesis. The steroid hormone precursor dehydroepiandrosterone (DHEA) is an endogenous uncompetitive inhibitor of G6PD. In humans, and a few other species, the sulfated circulatory form of DHEA (DHEAS) is present at extremely high concentrations – much higher than can be accounted for by DHEA's function as a precursor to steroid hormones. Uncompetitive inhibition is extremely rare in natural systems because it is irreversible in the presence of high concentrations of substrate and inhibitor. What has gone unappreciated is that such uncompetitive inhibition can quickly lead to cell death when the target is an obligatory housekeeping gene such as G6PD. Cells with inactivated p53 not only lose control over G6PD, but also over hexokinase (HK), the enzyme that converts glucose into glucose-6-phosphate (G6P), the substrate of G6PD. Furthermore, loss of p53 function de-represses NFκB activity, resulting in the upregulation of steroid sulfatase (SS) which converts circulating DHEAS into active DHEA. We propose that inactivation of p53 rapidly elevates G6P and DHEA concentrations in affected cells, driving uncompetitive inhibition of G6PD to lethal irreversibility. In animals with circulating DHEAS, this kill-switch mechanism may prevent most cases of p53 inactivation from becoming tumorigenic. Tumors would thus represent instances in which this mechanism had not been triggered, but which might still be triggered by application of DHEA sufficient to uncompetitively inhibit tumor G6PD. To test this hypothesis, we performed a pilot study in which dogs with cardiac hemangiosarcoma were treated with high dose (HD) DHEA supplemented with isoprene precursors to maintain geranylation of Rac GTPase. Tumor regression and longevity observed in these dogs supported the concept that some tumors retain extraordinary sensitivity to uncompetitive inhibition by DHEA.
In application/xml+jats format

Archived Files and Locations

application/pdf  901.4 kB
file_cqbb3l3zhfbmtbawpyypg3augu
web.archive.org (webarchive)
www.pagepressjournals.org (web)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2017-10-30
Container Metadata
Open Access Publication
Not in DOAJ
In ISSN ROAD
In Keepers Registery
ISSN-L:  2532-1250
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 33869a10-4827-4d55-b7b8-21015fe4def1
API URL: JSON